RTP Mobile Logo
Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)
Released April 2017

Highlights from video interviews with Drs Seth M Pollack and Brian A Van Tine on the treatment of soft tissue sarcomas.

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, radiation oncologists and other healthcare providers involved in the treatment of soft tissue sarcomas (STS).

    Sarcomas constitute a heterogeneous group of rare solid tumors of mesenchymal origin with distinct clinical and pathologic features. More than 50 different subtypes of STS exist in a variety of anatomic locations. Because of this heterogeneity and the historical lack of effective systemic therapeutic options, clinical decision-making for patients with STS has often been made on a case-by-case basis. However, significant research strides made during the past few years have led to the approval of new treatments for the disease in addition to the identification of a number of other novel agents demonstrating great promise. Featuring information on the latest clinical and research developments along with expert perspectives, this CME activity is designed to assist medical oncologists with the formulation of up-to-date clinical management strategies for the care of patients with STS.


    • Recognize the importance of multidisciplinary collaboration in the diagnosis and management of STS, and use this information to guide therapeutic decision-making.
    • Appreciate the recent FDA approvals of trabectedin, eribulin and olaratumab, and discern how these agents can be integrated into the clinical algorithm for patients with STS.
    • Appraise available efficacy data with pazopanib for patients with advanced STS, and assess how this agent can be optimally incorporated into current clinical practice.
    • Explore emerging data with immune checkpoint inhibitors, and use this information to counsel appropriate individuals regarding potential participation in ongoing trials.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Seth M Pollack, MD
    Assistant Member
    Clinical Research Division
    Fred Hutchinson Cancer Research Center
    Assistant Professor
    Division of Oncology
    University of Washington
    Seattle, Washington

    Advisory Committee: Amgen Inc, Lilly, Nektar; Consulting Agreements: Amgen Inc, Eisai Inc, Lilly; Contracted Research: EMD Serono Inc, Immune Design, Lilly, Merck.

    Brian A Van Tine, MD, PhD
    Assistant Professor of Medicine
    Department of Medicine at Washington University
    St Louis, Missouri

    Advisory Committee: Caris Life Sciences, EMD Serono Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Novartis; Contracted Research: Eisai Inc, Merck, Pfizer Inc; Paid Research: Eisai Inc, Merck; Speakers Bureau: Caris Life Sciences, GlaxoSmithKline, Novartis.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc, Janssen Biotech Inc and Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 20, 2017
    Expiration date: April 20, 2018

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Classification, incidence and management of sarcomas

  • Biology, incidence and management of sarcomas
  • Etiology and risk factors for the development of soft tissue sarcoma (STS)

Integration of the recently FDA-approved agents trabectedin and eribulin into the treatment algorithms for metastatic liposarcoma and leiomyosarcoma

  • Mechanism of action and tolerability of trabectedin for liposarcoma and leiomyosarcoma
  • ET743-SAR-3007: Progression-free survival benefit with trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy
  • Improvement in overall survival with eribulin versus dacarbazine for patients with previously treated advanced liposarcoma or leiomyosarcoma
  • Case discussion: A 55-year-old woman with Li-Fraumeni syndrome and a history of sarcoma is diagnosed with a high-grade, unresectable liposarcoma in the mediastinum
  • Integration of trabectedin and eribulin into the clinical management of leiomyosarcoma and liposarcoma
  • FDA approval of trabectedin for patients with unresectable or metastatic liposarcoma or leiomyosarcoma who experience disease progression after receiving an anthracycline regimen

Recent FDA approval of olaratumab in combination with doxorubicin and integration into the treatment algorithm for advanced STS

  • Use of the recently FDA-approved PDGFR alpha monoclonal antibody olaratumab in combination with doxorubicin as front-line therapy for advanced STS
  • Overall survival benefit with the addition of olaratumab to doxorubicin for patients with STS in the randomized Phase II JGDG trial
  • Mechanism of action, efficacy and tolerability of olaratumab

Role of tyrosine kinase inhibitors and immune checkpoint inhibitors in STS

  • Activity and tolerability of the tyrosine kinase inhibitors regorafenib and pazopanib in patients with STS
  • Use of pazopanib for patients with advanced STS
  • Activity of immune checkpoint inhibitors in patients with STS